162760-96-5
162760-96-5 結(jié)構(gòu)式
基本信息
N-(2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基)-N-(吡啶-2-基)環(huán)己甲酰胺
WAY100635
WAY100635 TRIHYDROCHLORIDE
WAY-100635
WAY 100635
WAY100635
Cyclohexanecarboxamide,N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-
N-{2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxaMide
CYCLOHEXANECARBOXAMIDE, N-[2-[4-(2-METHOXYPHENYL)-1-PIPERAZINYL]ETHYL]-N-2-PYRIDINYL-, HYDROCHLORIDE (1:3)
CYCLOHEXANECARBOXYLIC ACID (2-[4-(2-METHOXY-PHENYL)-PIPERAZIN-1-YL]-ETHYL)-PYRIDIN-2-YL-AMIDE TRIHYDROCHLORIDE
物理化學(xué)性質(zhì)
常見(jiàn)問(wèn)題列表
|
5-HT 1A Receptor 8.87 (pIC 50 ) |
5-HT 1A Receptor 9.71 (pA2) |
The functional properties and binding affinities of WAY-100635 are evaluated in HEK 293 cells stably expressing dopamine D
2L
or D
4.4
receptors.
WAY-100635 displays 940, 370, and 16 nM binding affinities at D
2L
, D
3
, and D
4.2
receptors, respectively. Saturation analyses demonstrat that the
K
d
of [
3
H] WAY-100635 at D
4.2
receptors is 2.4 nM. WAY-100635 is potent agonist in HEK-D
4.4
cells with
EC
50
of 9.7 nM. WAY-100635 possesses high affinity for D
4.4
receptor (3.3 nM) .
WAY-100635 (1 mg/kg; subcutaneous injection; male Sprague-Dawley rats) treatment abolishes the reduction of the severity of abstinence signs induced by Rhodiola rosea administration in nicotine-dependent rat.
| Animal Model: | Male Sprague-Dawley rats (220-240 g) |
| Dosage: | 1 mg/kg |
| Administration: | Subcutaneous injection (Pharmacokinetic study) |
| Result: | Reduced total abstinence score, increased immobility time and the burying behavior was increased. |